博雅生物(300294) - 2013 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2013 was CNY 245,278,066.33, representing a 7.93% increase compared to CNY 227,259,439.82 in 2012[15]. - Operating profit for 2013 was CNY 93,831,230.89, up 13.66% from CNY 82,556,925.44 in 2012[15]. - The total profit for 2013 reached CNY 97,759,343.00, a 10.26% increase from CNY 88,661,166.34 in 2012[15]. - Net profit attributable to ordinary shareholders was CNY 82,403,126.07, reflecting a 9.66% increase from CNY 75,146,190.16 in 2012[15]. - Basic earnings per share for 2013 were CNY 1.09, a 2.83% increase from CNY 1.06 in 2012[15]. - The net profit attributable to shareholders was 82.40 million yuan, reflecting a growth of 9.66% year-on-year[30]. - The net profit for the year was CNY 82,403,126.07, which contributed to the overall increase in equity[173]. - The net profit for the year was approximately RMB 76.62 million, showing a significant increase compared to the previous year[181]. Operating Costs and Expenses - The operating cost increased by 14.04% to CNY 106,274,429.39 in 2013 from CNY 93,186,848.33 in 2012[15]. - The total cost of goods sold increased by 14.04% to CNY 106.27 million, driven by higher material costs[43]. - The company's management expenses decreased to CNY 44,429,184.07 from CNY 48,116,031.89, a reduction of approximately 7.0% year-over-year[165]. - The financial expenses showed a significant increase in costs, moving from CNY -11,499,325.80 to CNY -17,047,960.21, indicating a rise in financial costs[165]. Cash Flow - The net cash flow from operating activities was CNY 89,106,522.68, showing a decrease of 3.52% compared to CNY 92,361,580.22 in 2012[15]. - The company reported a net cash flow from investing activities of CNY -178,214,399.10, an increase of 629.07% year-on-year[49]. - The cash dividend policy for the reporting period includes a distribution of 5.00 RMB per 10 shares, totaling 37,900,000 RMB, which represents 100% of the profit distribution[79]. - The cash inflow from financing activities was CNY 441,854,847.37, while the cash outflow was CNY 67,234,657.71, leading to a net cash flow from financing activities of CNY 374,620,189.66[171]. Assets and Liabilities - The total assets reached 1,004.47 million yuan, up by 29.21% from the previous year[16]. - The total liabilities increased significantly by 511.75% to 157.85 million yuan[16]. - The asset-liability ratio increased by 12.39 percentage points to 15.71%[16]. - The total liabilities rose to ¥157,845,086.01, up from ¥25,802,341.45, indicating a significant increase[160]. Research and Development - Research and development expenses amounted to 14.22 million yuan, a 28.61% increase from the previous year[35]. - The company established a new R&D center in Beijing with an investment of CNY 10 million to enhance its R&D capabilities[45]. - The company emphasizes enhancing its R&D capabilities through increased investment and collaboration with research institutions and enterprises[75]. - The company has a strong focus on research and development, aiming to enhance its product offerings and technological capabilities[185]. Shareholder and Equity Information - The total number of shares for the cash dividend distribution is based on 75,800,000 shares[81]. - The company distributed dividends totaling CNY 37,900,000.00, which affected the retained earnings[173]. - The total equity attributable to the parent company at the end of the year was CNY 846,624,685.28, compared to CNY 751,603,672.63 at the end of the previous year, indicating an increase of 12.6%[173]. - The company completed a public offering of 19,020,311 shares at a price of RMB 25.00 per share, raising a net amount of RMB 432,736,273.00 after deducting issuance costs[194]. Governance and Compliance - The company has established a management system for insider information to ensure compliance and protect shareholder interests[84]. - The company is committed to improving its governance structure and internal control systems to enhance risk management capabilities[76]. - The audit opinion for the financial statements was standard unqualified, indicating that the financial statements fairly represent the company's financial position[152]. - The company has implemented various internal control systems to enhance governance and compliance with regulations[142]. Market and Strategic Plans - The company plans to continue expanding its plasma collection stations and integrating resources in the pharmaceutical industry[34]. - The company aims to leverage its experience in the blood products industry to improve plasma utilization and enhance its supply chain capabilities[74]. - The company anticipates that the pharmaceutical industry will maintain a growth rate of over 20% annually due to favorable policies and market conditions[73]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[185].